MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN

Inclusion Criteria: Only those who fully meet the following criteria can be considered for inclusion in this study: 1. Age 5-17 years old; 2. SLE patients who meet the updated 2019 eular/acr SLE classification criteria or 2012 SLICC diagnostic criteria; 3. According to the revised International Society of Nephrology / Society of renal pathology (isn/rps) classification in 2018, it conforms to active proliferative ln type III or IV, with or without type V; 4. Glomerular filtration rate EGFR ≥ 60 ml/min/1.73 m2; 5. 24-hour urinary protein quantitation ≥ 25mg/kg, or urinary protein / creatinine 1.0mg/mg; 6. Blood routine WBC count ≥ 3.0\*10\^9/l, lymphocyte ≥ 0.5\*10\^9/l before enrollment; 7. No immunosuppressants such as cyclophosphamide, mycophenolate mofetil, cyclosporine A, tacrolimus, azathioprine, methotrexate, or biological agents such as rituximab, baileyoumab, and etaxel were used before enrollment. Exclusion Criteria: 1. A known history of primary immunodeficiency, splenectomy, or any potential disease that makes participants vulnerable to infection; 2. Evidence of hepatitis C, active hepatitis B, HIV infection, tuberculosis infection, severe fungal infection, or other serious infections; 3. Have any history of tumor or cancer; 4. Patients with lupus encephalopathy, diffuse alveolar hemorrhage, severe hemolytic anemia, blood routine platelet count lower than 10.0\*10\^9/l, glomerular filtration rate eGFR \< 60 ml/min/1.73 m2, or patients with other serious complications have unstable vital signs; 5. Have severe gastrointestinal bleeding, pancreatitis, serious heart, liver, blood, endocrine system diseases; 6. Patients who are known to be allergic to mycophenolate mofetil, cyclophosphamide, glucocorticoids or any of the above drugs; 7. Patients who participated in other clinical trials within 3 months before enrollment; 8. The researcher judged that the patient's condition was not suitable for participants in this trial.